Literature DB >> 9691915

Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role.

J F Quinton1, B Sendid, D Reumaux, P Duthilleul, A Cortot, B Grandbastien, G Charrier, S R Targan, J F Colombel, D Poulain.   

Abstract

BACKGROUND: Perinuclear antineutrophil cytoplasmic autoantibodies (pANCA) are a well recognised marker for ulcerative colitis. Antibodies to oligomannosidic epitopes of the yeast Saccharomyces cerevisiae (ASCA) are a new marker associated with Crohn's disease. AIMS: To assess the value of detecting pANCA and/or ASCA for the diagnosis of ulcerative colitis and Crohn's disease.
METHODS: Serum samples were obtained from 100 patients with Crohn's disease, 101 patients with ulcerative colitis, 27 patients with other miscellaneous diarrhoeal illnesses, and 163 healthy controls. Determination of pANCA and ASCA was performed using the standardised indirect immunofluorescence technique and an ELISA, respectively.
RESULTS: The combination of a positive pANCA test and a negative ASCA test yielded a sensitivity, specificity, and positive predictive value of 57%, 97%, and 92.5% respectively for ulcerative colitis. The combination of a positive ASCA test and a negative pANCA test yielded a sensitivity, specificity, and positive predictive value of 49%, 97%, and 96% respectively for Crohn's disease. Among patients with miscellaneous non-inflammatory bowel disorders, three were ASCA positive and two were pANCA positive. One control was ASCA positive. The presence of ASCA in patients with Crohn's disease was associated with small bowel involvement.
CONCLUSION: ASCA and pANCA are strongly associated with Crohn's disease and ulcerative colitis, respectively. Combination of both tests could help the diagnosis of inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9691915      PMCID: PMC1727156          DOI: 10.1136/gut.42.6.788

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  21 in total

1.  Antibodies to Saccharomyces cerevisiae in patients with Crohn's disease and their possible pathogenic importance.

Authors:  M H Giaffer; A Clark; C D Holdsworth
Journal:  Gut       Date:  1992-08       Impact factor: 23.059

2.  Cortisone in ulcerative colitis; final report on a therapeutic trial.

Authors:  S C TRUELOVE; L J WITTS
Journal:  Br Med J       Date:  1955-10-29

3.  A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease.

Authors:  A Saxon; F Shanahan; C Landers; T Ganz; S Targan
Journal:  J Allergy Clin Immunol       Date:  1990-08       Impact factor: 10.793

4.  Anti-neutrophil cytoplasmic antibodies in ulcerative colitis. Comparison with other colitides/diarrheal illnesses.

Authors:  R H Duerr; S R Targan; C J Landers; L R Sutherland; F Shanahan
Journal:  Gastroenterology       Date:  1991-06       Impact factor: 22.682

5.  Delineation of a standard procedure for indirect immunofluorescence detection of ANCA.

Authors:  A Wiik
Journal:  APMIS Suppl       Date:  1989

6.  Serum antibodies reactive with Saccharomyces cerevisiae in inflammatory bowel disease: is IgA antibody a marker for Crohn's disease?

Authors:  R M Barnes; S Allan; C H Taylor-Robinson; R Finn; P M Johnson
Journal:  Int Arch Allergy Appl Immunol       Date:  1990

7.  A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease.

Authors:  J A Rump; J Schölmerich; V Gross; M Roth; R Helfesrieder; A Rautmann; J Lüdemann; W L Gross; H H Peter
Journal:  Immunobiology       Date:  1990-11       Impact factor: 3.144

8.  Anti-neutrophil antibodies in inflammatory bowel disease: prevalence and diagnostic role.

Authors:  G Cambridge; D S Rampton; T R Stevens; D A McCarthy; M Kamm; B Leaker
Journal:  Gut       Date:  1992-05       Impact factor: 23.059

9.  Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease.

Authors:  J Main; H McKenzie; G R Yeaman; M A Kerr; D Robson; C R Pennington; D Parratt
Journal:  BMJ       Date:  1988-10-29

10.  Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI).

Authors:  W R Best; J M Becktel; J W Singleton
Journal:  Gastroenterology       Date:  1979-10       Impact factor: 22.682

View more
  155 in total

1.  Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease.

Authors:  C L Sutton; H Yang; Z Li; J I Rotter; S R Targan; J Braun
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

Review 2.  Diagnostic methodologies: serology, endoscopy, and radiology.

Authors:  T Dassopoulos
Journal:  Curr Gastroenterol Rep       Date:  2001-12

3.  Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics.

Authors:  E A Vasiliauskas; L Y Kam; L C Karp; J Gaiennie; H Yang; S R Targan
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

Review 4.  Serologic testing in inflammatory bowel disease: its value in indeterminate colitis.

Authors:  K A Papadakis; S R Targan
Journal:  Curr Gastroenterol Rep       Date:  1999-12

Review 5.  Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)?

Authors:  C Roozendaal; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

Review 6.  Evaluation of inflammatory activity in Crohn's disease and ulcerative colitis.

Authors:  Eduardo Garcia Vilela; Henrique Osvaldo da Gama Torres; Fabiana Paiva Martins; Maria de Lourdes de Abreu Ferrari; Marcella Menezes Andrade; Aloísio Sales da Cunha
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

Review 7.  Recent advances in the diagnosis and classification of inflammatory bowel disease.

Authors:  Eric Vasiliauskas
Journal:  Curr Gastroenterol Rep       Date:  2003-12

8.  Anti-saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy.

Authors:  I E A Hoffman; P Demetter; M Peeters; M De Vos; H Mielants; E M Veys; F De Keyser
Journal:  Ann Rheum Dis       Date:  2003-05       Impact factor: 19.103

9.  Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density.

Authors:  M T Abreu; V Kantorovich; E A Vasiliauskas; U Gruntmanis; R Matuk; K Daigle; S Chen; D Zehnder; Y-C Lin; H Yang; M Hewison; J S Adams
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

10.  Systemic antibodies towards mucosal bacteria in ulcerative colitis and Crohn's disease differentially activate the innate immune response.

Authors:  E Furrie; S Macfarlane; J H Cummings; G T Macfarlane
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.